Rheumatoid arthritis drugs market will reach $34.6bn in 2020, according to new visiongain analysis

04 September 2018
Pharma

A new report published by visiongain in July 2016 forecasts that overall sales of drugs for rheumatoid arthritis (RA) will generate revenues of $34.6bn in 2020. Sales will grow until 2018, and then decline as the many of the leading TNF inhibitors lose patent protection and biosimilars become more prominent.

That revenue prediction and others appear in Rheumatoid Arthritis (RA) Drugs Market 2016-2026 – Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs and Other Agents) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets (US, Japan the EU5 and BRIC); and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations assess potentials of industries and markets in healthcare and other fields.

Its new investigation predicts that, in the years after 2018, biosimilars will be widely available, the market will become saturated with products, and there will be a strong downward pressure on product pricing. Research and development holds potential, however, with new products expected to change that market.

In 2015, biologics were the dominant source of revenue for manufacturers, accounting for 92.3% of the global drug market for RA. However the study shows that segment will decline in market share over the forecast period as leading products such as AbbVie’s Humira (adalimumab), Amgen/Pfizer’s Enbrel (etanercept) and J&J/Merck’s Remicade (infliximab) face strong competition from biosimilars and newer biologics.

Alastair McDougall, a pharmaceutical industry analyst in visiongain, said: “The TNF inhibitors have been very lucrative drugs for manufacturers, but very expensive ones for patients. The rise to prominence of the biosimilars provides a way of reducing the cost of treatment but retaining the same level of efficacy. The introduction of new biologics, such as IL-6 inhibitors, could provide more-targeted drugs with greater levels of efficacy, while the arrival of new JAK inhibitors and BTK inhibitors could provide oral treatments which reduce the need for biologics. There are a lot of opportunities for new drugs in RA, and it is going to be interesting to see how the market develops.”

Along with revenue prediction for the overall world market for treating rheumatoid arthritis, visiongain’s work shows revenue forecasts to 2026 for two main submarkets:

• Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
• Non-biologics (other therapeutic molecules).

For the non-biologics submarket, that work shows three further revenue breakdowns to 2026:

• NSAIDs
• sDMARDs
• Others agents (grouped).

The study then shows revenue predictions to 2026 for 11 products, including the following drugs:

• Humira (adalimumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Rituxan (rituximab)
• Actemra (tocilizumab)
• Orencia (abatacept).

In addition, the analysis covers prominent national markets for RA drug sales, with revenue forecasts to 2026 for these 11 countries:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

The survey examines leading pharmaceutical companies in that market, discussing mergers and acquisitions, collaborations and R&D, as well as recent sales results. Companies covered include these:

• AbbVie
• Roche
• J&J
• Amgen
• Pfizer
• Merck & Co.

Rheumatoid Arthritis (RA) Drugs Market 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services. Each year new and updated studies appear.

Recent News

“The colon targeting drug delivery market will grow with exponential growth of 14% over the forecast period from 2020-2030”, says Visiongain

The colon targeting drug delivery market has been used various polymers including biodegradable polymers, guar gum, pectin, chondroitin sulfate, dextran, chitosan, cyclodextrin, inulin, amylose, locust bean gum, and others

23 September 2019

Read

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!